Skip to main content

Invitrogen Licenses Geron's Patents on Human Embryonic Stem Cells

NEW YORK (GenomeWeb News) - Geron licensed its intellectual property related to the growth of human embryonic stem cells to Invitrogen, Invitrogen said today.
 
Under the non-exclusive license agreement, Invitrogen can use Geron's patents to develop, manufacture, and sell media, additives, and reagents for use by hESC researchers. Some commercial use restrictions apply.
 
Invitrogen can also sublicense the products to its customers for research use only. Geron will receive license payments and royalties on products developed using the patents.
 
The license involves patents covering the growth of hESCs in the absence of feeder cells, and those covering specific media formulations for such feeder-free growth.
 
Additional financial details were not disclosed.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.